Asset profile
BL-M11D1
Antibody–drug conjugate
Evidence outlook · registrational
Acute Myeloid Leukemia: registrational readout pending
Its supporting mid-stage evidence has not yet been graded on this platform. Registrational readout expected around 2027-12.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
64 competitors in this universe: 4 direct rivals (same mechanism and indication), 0 same-class, 60 same-indication; 30 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| BL-M11D1: this drug | Phase 2/3 | Antibody–drug conjugate | CD33 | ||
| Gemtuzumab Ozogamicin | Approved | Antibody–drug conjugate | CD33 | ||
| Lintuzumab-Ac225 | Phase 3 | Radiopharmaceutical | CD33 | ||
| Anti-CD33 CAR T-Cells | Phase 1/2 | Biologic (subtype unspecified) | CD33 | ||
| PRGN-3006 T Cells | Phase 1 | Cell therapy | CD33 | ||
| ASTX727 | Approved | Small molecule | Decitabine/cedazuridine fixed combination (DNMT + CDA inhibition) | ||
| Enasidenib | Approved | Small molecule | IDH2 | ||
| Gilteritinib | Approved | Small molecule | FLT3 | ||
| Midostaurin | Approved | Small molecule | FLT3;KIT;PKC;PDGFR | ||
| Olutasidenib | Approved | Small molecule | Mutant IDH1 | ||
| Quizartinib | Approved | Small molecule | FLT3 | ||
| Revumenib | Approved | Small molecule | Menin | ||
| Tretinoin (Vesanoid) | Approved | Small molecule | RARA (retinoic acid receptor alpha); degrades the PML-RARA fusion oncoprotein in APL | ||
| Venetoclax | Approved | Small molecule | BCL-2 | ||
| Vyxeos | Approved | Small molecule | DNA synthesis (cytarabine, antimetabolite) / Topoisomerase II | ||
| 131I-Apamistamab | Phase 3 | Monoclonal antibody | CD45 |
…and 49 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
(3 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (1)
December 2026 (1)
What to watch
2027 (1)
December 2027 (1)
What to watch
2028 (1)
December 2028 (1)
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.